Janssen Pharmaceutical Inc.
1125 Trenton-Harbourton Road
Titusville
New Jersey
08560
United States
Tel: 609-730-2000
225 articles with Janssen Pharmaceutical Inc.
-
As the American Society of Clinical Oncology 2019 Genitourinary Cancers Symposium (ASCO GU) rolls on, companies are showcasing more data in presentations. BioSpace takes a look at some of the latest.
-
FDA Advisory Committee Recommends Approval of SPRAVATO™ (esketamine) Nasal Spray CIII for Adults with Treatment-Resistant Depression
2/12/2019
If approved, SPRAVATO™ will offer the first new mechanism of action in 30 years to treat this debilitating disease, continuing Janssen's 60-plus-year history and commitment to research that make a difference for people living with mental illnesses, including severe mood disorders
-
U.S. FDA Approves DARZALEX® (daratumumab) Split-Dosing Regimen
2/12/2019
The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has approved a split-dosing regimen for DARZALEX® (daratumumab), providing healthcare professionals and patients with multiple myeloma an option to split the first infusion over two consecutive days.
-
Thomas Wicks, chief strategy officer of New Jersey-based TrialScope, said transparency has picked up over the past few years, particularly as large pharma companies have begun to release information about their own clinical efforts.
-
Drake Bell, Ryan Eggold, Nigel Barker, Erich Bergen, Countess Luann, Sonja Morgan, and more Participate in Third Annual Blue Jacket Fashion Show to Benefit the Prostate Cancer Foundation
2/8/2019
Mario Cantone, Buster Skrine, Dominic Fumusa, Harry Lennix, Michael Kors, Ryan Seacrest Distinction, John Varvatos, Bruno Magli, Stephen Ferber, Brooks Brothers and others additionally participate in national awareness campaign
-
Janssen Enters Worldwide Collaboration and License Agreement with MeiraGTx to Develop Gene Therapy Programs for Inherited Retinal Diseases
1/31/2019
The Janssen Pharmaceutical Companies of Johnson & Johnson announced a worldwide collaboration and license agreement with MeiraGTx Holdings plc.
-
Janssen Pharmaceutical, a Johnson & Johnson company, inked a worldwide collaboration and license deal with MeiraGTx to develop, manufacture and commercialize a portfolio of drugs for inherited retinal diseases.
-
U.S. FDA Approves IMBRUVICA® (ibrutinib) Plus Obinutuzumab as First Non-Chemotherapy Combination Regimen for Treatment-Naïve Patients with Chronic Lymphocytic Leukemia
1/28/2019
Patients treated with IMBRUVICA plus obinutuzumab experienced a 77 percent reduction in risk of progression or death compared to chlorambucil plus obinutuzumab
-
The approval of the combination marks a first for the U.S. market. The combination of AbbVie and Janssen’s Imbruvica with Roche’s Gazyva is the first chemotherapy-free, anti-CD20 combination to treat CLL and SLL patients who have not yet started therapy, AbbVie said this morning.
-
Janssen Pharmaceuticals and Apple have teamed up to determine if a new app for the Apple Watch, which has a built-in electrocardiogram can improve the health of more than 30 million people with atrial fibrillation (AFib), a condition that can lead to stroke and other potentially devastating compl...
-
Johnson & Johnson Announces Research Study with Apple Watch to Help Improve AFib Outcomes Including Stroke Prevention
1/17/2019
Johnson & Johnson to collaborate with Apple to assess impact of wearable technology on earlier detection of AFib, improved diagnosis and patient outcomes
-
Although that is good news, cancer is the second-most common cause of death in the U.S., with more than 1.7 million new cancer cases each year and more than 600,000 cancer deaths. The report notes that one of the biggest factors in decreased cancer rates are lower tobacco smoking rates.
-
The researchers identified a group of centyrins that blocked the action of five toxins generated by Staphylococcus aureus, the bacteria that causes Staph infections.
-
In 2018, the FDA approved 59 novel drugs, meaning approved new molecular entities. BioSpace analyzed new drug approvals from 2014 to 2018 to determine which companies were responsible for the most drug approvals in that period. Here’s a look.
-
Winterlight Labs, Inc. Enters Collaboration with Johnson & Johnson Innovation to Develop a Digital Biomarker for Diagnosis of Early Stage Alzheimer's Disease
1/7/2019
Winterlight Labs, Inc. announced today that it has entered a collaboration with Janssen Pharmaceuticals, Inc. ("Janssen"), one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
-
Under the terms of the deal, Janssen is paying Locus $20 million up front. Locus will be eligible for up to a total of $798 million in development and commercial milestones, as well as royalties on any product sales.
-
In writing literally hundreds of stories this year, two BioSpace writers, Alex Keown and Mark Terry, found certain stories particularly intriguing or impactful. Some of those were such big topics that they were covered over a series of stories. Looking back at 2018, here are their Top 10.
-
Janssen Signs Results-Based Contract with Oklahoma Health Care Authority (OHCA) for its Long-Acting Injectable Schizophrenia Medicines
12/13/2018
With INVEGA SUSTENNA® and INVEGA TRINZA®, medicines shown to delay patient relapse, OHCA aims to reduce Medicaid costs, improve patient care
-
MorphoSys's Licensee Janssen Announces Data from the Phase 3 Head-to-Head Study ECLIPSE Demonstrating Superiority of Tremfya(R) vs. Cosentyx(R) as Measured by PASI 90 at Week 48 in the Treatment of Plaque Psoriasis
12/12/2018
MorphoSys AG reported today that its licensee Janssen has announced that results from the ECLIPSE study demonstrated that Tremfya(R) (guselkumab) was superior to Cosentyx(R) (secukinumab) in treating adults with moderate to severe plaque psoriasis for the primary endpoint of a PASI 90 response at week 48.
-
New Phase 3 data demonstrate superiority of TREMFYA® (guselkumab) vs Cosentyx® (secukinumab) in delivering PASI 90 responses in the treatment of moderate to severe plaque psoriasis at week 48
12/12/2018
84.5 percent of patients receiving TREMFYA achieved the primary endpoint of a PASI 90 response at week 48 compared with 70.0 percent of patients receiving Cosentyx